

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
06 January 2022 (06.01.2022)



(10) International Publication Number
WO 2022/006492 A3

(51) International Patent Classification:

C12N 9/24 (2006.01) A61P 35/00 (2006.01)
A61K 38/47 (2006.01) A61K 39/00 (2006.01)

(21) International Application Number:

PCT/US2021/040240

(22) International Filing Date:

02 July 2021 (02.07.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/047,989 03 July 2020 (03.07.2020) US
63/134,411 06 January 2021 (06.01.2021) US

(71) Applicant: **PALLEON PHARMACEUTICALS INC.**
[US/US]; 266 Second Avenue, 2nd Floor, Waltham, Mass-
achusetts 02451 (US).

(72) Inventors: **PENG, Li**; 6 Bicentennial Drive, Lexington,
Massachusetts 02421 (US). **SHELKE, Sandip A.**; 55 Hill
Road, Belmont, Massachusetts 02478 (US). **CAO, Lizhi**;

23 Highland Avenue, Stoneham, Massachusetts 02180
(US).


(74) Agent: **GUSTAFSON, Megan A.**; GOODWIN PROC-
TER LLP, 100 Northern Avenue, IP Docketing Dept/7th
Floor, Boston, Massachusetts 02210 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

(54) Title: RECOMBINANT SIALIDASES WITH REDUCED PROTEASE SENSITIVITY, SIALIDASE FUSION PROTEINS,
AND METHODS OF USING THE SAME

FIGURE 1



(57) Abstract: The invention relates generally to recombinant sialidases (for example, recombinant sialidases having reduced protease sensitivity), recombinant fusion proteins, and antibody conjugates, and their use in the treatment of cancer.

[Continued on next page]

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:

17 February 2022 (17.02.2022)